c-Myc siRNA (h) from Santa Cruz Biotechnology, Inc.

Product Specs
Itemc-Myc siRNA (h)
CompanySanta Cruz Biotechnology, Inc.
Price $293.00Supplier Page View Company Product Page
Catalog Numbersc-29226
Gene Namev-myc myelocytomatosis viral oncogene homolog (avian)
Quantity10 µM
Specieshuman
NCBI Full Gene NameMYC proto-oncogene, bHLH transcription factor
NCBI Gene AliasesMRTL, MYCC, bHLHe39, c-Myc
TypesiRNA/dsRNA

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Combinational Inhibition of the eIF4F Complex, AKT1, and EZH2 Enhances Anticancer Effects in BRAF^V600E Mutant A375 Melanoma CellsOncology ResearchFebruary 24, 2026Yuanxin Miao, Fengyun Hao, Sae Hwi Ki(Santa Cruz, Dallas, TX, USA), including: eIF4E siRNA (sc-35284), BMF siRNA(sc-45930), c-Myc siRNA(sc-29226), c-Jun siRNA (sc-29223), c-Fos siRNA (sc-44200), and EGR1 siRNA (sc-44203). EZH2 siRNA (#6509) was

(2) Modulatory Effect of Curcumin on Expression of Methyltransferase/Demethylase in Colon Cancer Cells: Impact on wt p53, mutp53 and c-MycMoleculesJuly 22, 2025Roberta Santarelli, Claudia Di Dio, Michele Di Crosta, Paola Currà, Roberta Gonnella, Mara Cironetransfected with either c-Myc-specific siRNA (si c-Myc; Santa Cruz Biotechnology Inc., Dallas, TX, USA, sc-29226) or Control siRNA-A (scrambled, Scr; Santa Cruz Biotechnology Inc., Dallas, TX, USA, sc-37007), using

(3) Identification of Transcriptional Regulators of Immune Evasion Across Cancers: An Alternative Immunotherapeutic Strategy for CholangiocarcinomaCancers (Basel)December 17, 2024Simran Venkatraman, Brinda Balasubramanian, Pornparn Kongpracha, Supaporn Yangngam, Nisa Chuangchot, Suparada Khanaruksombat, Suyanee Thongchot, Monthira Suntiparpluacha, Kyaw Zwar Myint, Sunhapas Soodvilai, et al.at 37 °C with 5% CO2. 2.9. Lipofectamine Transfection for MYC Knockdown The siRNA of MYC (human) (sc-29226) was purchased from Santa Cruz (Santa Cruz Biotechnology, Dallas, TX, USA). The lipofectamine reagent

(4) Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancerJournal of Experimental MedicineNovember 4, 2024Zhen Chen, Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana Leal, Suresh S. Ramalingam, Shi-Yong SunGene knockdown using siRNA and shRNA hTERT siRNA (sc-36641), hTERT shRNA plasmid (sc-36641-SH), c-Myc siRNA (sc-29226), and c-Myc shRNA plasmid (sc-29226-SH) were purchased from Santa Cruz Biotechnology. Scrambled control

(5) Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung CancerAdvanced ScienceJuly 23, 2024Zhen Chen, Karin A. Vallega, Vijay K. Boda, Zihan Quan, Dongsheng Wang, Songqing Fan, Qiming Wang, Suresh S. Ramalingam, Wei Li, Shi‐Yong Sundescribed previously.[ 58 ] Gene Knockdown using siRNA and shRNA TRPM2 siRNA (sc‐42674), c‐Myc siRNA (sc‐29226), VDR siRNA (sc‐106692), and VDR shRNA plasmid (sc‐106692‐SH) were purchased from Santa Cruz Biotechnology.

(6) USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticityMolecular cancerDecember 13, 2023Kwon J, Zhang J, Mok B, Allsup S, Kim C, Toretsky J, Han C.(protein). To knock down MYC protein, the following control siRNA (Cat#sc-37007) and siMYC RNA (Cat#sc-29226) were purchased from Santa Cruz and transfected into cells using siRNA Transfection Reagent (Cat#sc-29528)

(7) NFE2L2 and STAT3 Converge on Common Targets to Promote Survival of Primary Lymphoma CellsInternational journal of molecular sciencesJuly 18, 2023Arena A, Di Crosta M, Gonnella R, Zarrella R, Romeo MA, Benedetti R, Gilardini Montani MS, Santarelli R, D'Orazi G, Cirone M.transfected with 1.8 pmol of NFE2L2 (NRF2)-siRNA (siNRF2, Santa Cruz Biotechnology Inc., Dallas, TX, USA, sc-29226), STAT3-siRNA (siSTAT3, Santa Cruz Biotechnology Inc., Dallas, TX, USA, sc-29493), and p62/SQSTM1-siRNA

(8) mTORC1-c-Myc pathway rewires methionine metabolism for HCC progression through suppressing SIRT4 mediated ADP ribosylation of MAT2ACell & bioscienceNovember 12, 2022Zhao L, Su H, Liu X, Wang H, Feng Y, Wang Y, Chen H, Dai L, Lai S, Xu S, et al.

(9) Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomasMolecular cellOctober 20, 2022Shi Z, Ge X, Li M, Yin J, Wang X, Zhang J, Chen D, Li X, Wang X, Ji J, et al.

(10) c-Myc Sustains Pancreatic Cancer Cell Survival and mutp53 Stability through the Mevalonate PathwayBiomedicinesOctober 5, 2022Romeo MA, Gilardini Montani MS, Arena A, Benedetti R, D'Orazi G, Cirone M.transfected the following day with c-Myc siRNA (si c-Myc, Santa Cruz Biotechnology Inc., Dallas, TX, USA, sc-29226) using INTERFERin® (Polyplus-transfection, Illkirch, France) according to the manufacturer’s instructions.

(11) PLEK2 promotes cancer stemness and tumorigenesis of head and neck squamous cell carcinoma via the c-Myc-mediated positive feedback loopCancer communications (London, England)October 1, 2022Zhao X, Shu D, Sun W, Si S, Ran W, Guo B, Cui L.

(12) Transcription factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expressionCell communication and signaling : CCSSeptember 19, 2022Sun T, Zhang K, Li W, Liu Y, Pangeni RP, Li A, Arvanitis L, Raz DJ.

(13) Targeting c-Myc Unbalances UPR towards Cell Death and Impairs DDR in Lymphoma and Multiple Myeloma CellsBiomedicinesMarch 22, 2022Arena A, Romeo MA, Benedetti R, Gilardini Montani MS, Cirone M.per well and transfected with c-Myc siRNA (si c-Myc, Santa Cruz Biotechnology Inc., Dallas, TX, USA, sc-29226), for knockdown, or Control siRNA-A (scramble, SCR, Santa Cruz Biotechnology Inc., Dallas, TX, USA,

(14) KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathwayBreast cancer research : BCRJanuary 25, 2022Yin L, Li Q, Mrdenovic S, Chu GC, Wu BJ, Bu H, Duan P, Kim J, You S, Lewis MS, et al.

(15) DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replicationBiochimica et biophysica acta. Molecular cell researchJanuary 1, 2022Arena A, Gilardini Montani MS, Romeo MA, Benedetti R, Gaeta A, Cirone M.

(16) TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivityInternational journal of biological sciencesJanuary 1, 2022Liu Q, Chung S, Murata MM, Han B, Gao B, Zhang M, Lee TY, Chirshev E, Unternaehrer J, Tanaka H, et al.#sc 37007), RAD17 siRNA (Santa Cruz Biotechnology # sc 36358) or MYC siRNA (Santa Cruz Biotechnology #sc-29226) was transfected into cells using DharmaFECT 3 (Dharmacon #T-2003-01). pcDNA3-EV, pcDNA3-MYC (from the

(17) Knockdown of c-MYC Controls the Proliferation of Oral Squamous Cell Carcinoma Cells in vitro via Dynamic Regulation of Key Apoptotic Marker GenesInternational journal of molecular and cellular medicineDecember 1, 2021Sabit H, Tombuloglu H, Cevik E, Abdel-Ghany S, El-Zawahri E, El-Sawy A, Isik S, Al-Suhaimi E.

(18) ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cellsPLoS pathogensNovember 1, 2021Van Sciver N, Ohashi M, Nawandar DM, Pauly NP, Lee D, Makielski KR, Bristol JA, Tsao SW, Lambert PF, Johannsen EC, et al.Flores at the Moffitt Cancer Center. siRNAs siRNAs against ΔNp63ɑ (sc-36161A, sc-36161B), c-myc (sc-29226, sc-44248), MAPK14 (sc-29433), and control siRNAs A and C (sc-37007, sc-44231) were purchased from Santa Cruz

(19) Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer CellsCellsSeptember 12, 2021Steifensand F, Gallwas J, Bauerschmitz G, Gründker C.in 25 cm2 cell culture flask. The cells were transiently transfected with siRNA specific to c-Myc (sc-29226 c-Myc-specific siRNA; Santa Cruz Biotechnology, Dallas, TX, USA) in OPTI-MEM I medium (Gibco, Carlsbad,

(20) The chromatin modifier MORC2 affects glucose metabolism by regulating the expression of lactate dehydrogenase A through a feed forward loop with c-MycFEBS lettersMay 1, 2021Guddeti RK, Thomas L, Kannan A, Karyala P, Pakala SB.

Be the First to Write a Review!

c-Myc siRNA (h)

c-Myc siRNA (h) from Santa Cruz Biotechnology, Inc.

Description

Santa Cruz Biotechnology, Inc.

Citations (86)

Reviews

c-Myc siRNA (h) from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map